Semma Therapeutics
Cambridge
About Semma Therapeutics
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients. Recent work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. This breakthrough technology has been exclusively licensed to Semma Therapeutics for the development of a cell-based therapy for diabetes. Ongoing research at Semma Therapeutics is focused on combining these proprietary cells with a state-of-the-art device to provide a true replacement for the missing beta cells in a diabetic patient without immunosuppression. Semma Therapeutics is working to bring this new therapeutic option to the clinic and improve the lives of patients with diabetes.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $10K – $50K
- Total funding: $163.0M
- Funding stage: M&A
- Last round: Series B (Nov 2017)
- Website: semma-tx.com
- Phone: (857)529-6430
Industries & Categories
Biotechnology, Health Care, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/semma-therapeutics-107279 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.